Nektar Therapeutics NKTR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.1M-12.7% | -$164.08M-30.0% | -$128M+23.9% | -$129.53M+26.9% | -$140.3M+20.2% | ||
| $751K-76.6% | $1.03M-76.6% | $1.17M-79.5% | $1.97M-69.4% | $3.21M-54.9% | ||
| $12.11M-37.9% | $12.65M-41.5% | $15.26M-36.6% | $17.58M-34.5% | $19.51M-33.6% | ||
| -$7.97M-179% | -$625K-123% | $7.86M— | $8.82M— | $10.07M— | ||
| -$4.67M— | -$5.79M— | —— | —— | —— | ||
| $9.53M+3.9% | $16.43M+293% | $9M— | $11.96M— | $9.17M— | ||
| -$6.02M-34.9% | -$8.73M— | -$7.38M— | -$6.85M— | -$4.46M— | ||
| -$5.85M+22.0% | -$5.51M+40.4% | -$5.16M+54.8% | -$5.79M+55.7% | -$7.51M+47.2% | ||
| -$203.76M-15.2% | -$208.51M-18.7% | -$189.74M-7.5% | -$184.91M-5.8% | -$176.87M+6.2% | ||
| $187K-85.8% | $171K-88.4% | $612K-50.9% | $1.16M+89.9% | $1.31M+123% | ||
| $712.33M+292% | $285.01M+8.9% | $263.24M-20.4% | $132.06M-69.7% | $181.58M-64.4% | ||
| $316.85M+11.1% | $284.68M-16.4% | $257.81M+218% | $268.17M+353% | $285.21M+1,310% | ||
| —— | —— | $58.65M-41.2% | $199.63M+81.4% | $167M+41.3% | ||
| —— | $866K+634% | $539K+1,047% | $314K+824% | $122K+270% | ||
| $710.11M+581,956% | $180.57M+329% | $141.98M+238% | $314K-99.3% | $122K-99.7% | ||
| $7K— | $6K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$9.75M— | ||
| $12.11M-37.9% | $12.65M-41.5% | $15.26M-36.6% | $17.58M-34.5% | $19.51M-33.6% | ||
| -$5.85M+22.0% | -$5.51M+40.4% | -$5.16M+54.8% | -$5.79M+55.7% | -$7.51M+47.2% | ||
| —— | $0-100% | $10.1M-66.7% | $20.2M0.0% | $30.29M+200% | ||
| -$6.02M-34.9% | -$8.73M— | -$7.38M— | -$6.85M— | -$4.46M— | ||
| $15.75M+34.0% | $15.16M+17.5% | $14.69M+41.4% | $14.29M+53.2% | $11.76M+17.3% | ||
| -$4.67M— | -$5.79M— | —— | —— | —— | ||
| $9.53M+3.9% | $16.43M+293% | $9M— | $11.96M— | $9.17M— | ||
| $29.15M+5.8% | $26.18M-6.9% | $26.57M+7.0% | $26.54M+7.4% | $27.56M+12.7% | ||
| $55.33M-6.6% | $54.93M-14.5% | $49.36M-25.3% | $53.6M-21.8% | $59.22M-12.4% | ||
| —— | —— | —— | —— | —— | ||
| $316.85M+11.1% | $284.68M-16.4% | $257.81M-40.3% | $268.17M-50.8% | $285.21M-54.5% | ||
| —— | -$697K-101% | $15.82M— | $32.34M— | $48.87M— | ||
| —— | —— | —— | —— | —— | ||
| $4.91M+3,928% | $866K+634% | $539K+1,047% | $314K+824% | $122K+270% | ||
| —— | $0-100% | $3.05M-66.7% | $6.11M0.0% | $9.16M+200% | ||
| —— | $0-100% | $174.25K-66.7% | $348.5K0.0% | $522.75K+200% | ||
| -$203.94M-14.5% | -$208.68M-17.8% | -$190.35M-7.1% | -$186.07M-6.1% | -$178.19M+5.8% | ||
| -$203.94M-14.5% | -$208.68M-17.8% | -$190.35M-7.1% | -$186.07M-6.1% | -$178.19M+5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.